Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset

Richard Allen, Sally Y. Ritchie

Research output: Contribution to journalArticle

Abstract

Objective: To determine whether clinical response to the dopamine agonist, ropinirole, in the treatment of primary restless legs syndrome (RLS), depends upon the age-at-onset of RLS symptoms. Methods: Pooled data from four 12-week, randomized, double-blind, placebo-controlled studies of ropinirole in patients with moderate-to-severe primary RLS were analyzed post hoc. The relationship between age-at-onset and response to treatment, based on change from the baseline International Restless Legs Syndrome Study Group (IRLSSG) rating scale (the International Restless Legs Scale [IRLS]) total score and the proportion of responders (rated 'much'/'very much' improved) on the Clinical Global Impression-Improvement (CGI-I) scale, was explored. Results: The range of age-at-onset of RLS symptoms was 2-75 years. No relationship was observed between the age-at-onset of RLS symptoms and baseline IRLS total score (correlation r = -0.06), and between dose administered at Week 12 last observation carried forward (LOCF) and age-at-onset (r = -0.04). The age-at-onset by treatment interaction was non-significant (P = 0.952 for the IRLS and P = 0.716 for the CGI-I scale), indicating there was no significant relationship between age-at-onset and the magnitude of ropinirole treatment effect. Conclusions: These data suggest that ropinirole provides effective relief of symptoms, regardless of age at RLS symptom onset.

Original languageEnglish (US)
Pages (from-to)899-902
Number of pages4
JournalSleep Medicine
Volume9
Issue number8
DOIs
StatePublished - Dec 2008

Fingerprint

Restless Legs Syndrome
Age of Onset
ropinirole
Dopamine Agonists
Therapeutics
Placebos
Observation

Keywords

  • Dopamine agonist
  • Early-onset RLS
  • Late-onset RLS
  • Restless legs syndrome
  • RLS
  • RLS onset age
  • Ropinirole

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. / Allen, Richard; Ritchie, Sally Y.

In: Sleep Medicine, Vol. 9, No. 8, 12.2008, p. 899-902.

Research output: Contribution to journalArticle

@article{cc8ce5a09a584d5eba05a63a4a83441f,
title = "Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset",
abstract = "Objective: To determine whether clinical response to the dopamine agonist, ropinirole, in the treatment of primary restless legs syndrome (RLS), depends upon the age-at-onset of RLS symptoms. Methods: Pooled data from four 12-week, randomized, double-blind, placebo-controlled studies of ropinirole in patients with moderate-to-severe primary RLS were analyzed post hoc. The relationship between age-at-onset and response to treatment, based on change from the baseline International Restless Legs Syndrome Study Group (IRLSSG) rating scale (the International Restless Legs Scale [IRLS]) total score and the proportion of responders (rated 'much'/'very much' improved) on the Clinical Global Impression-Improvement (CGI-I) scale, was explored. Results: The range of age-at-onset of RLS symptoms was 2-75 years. No relationship was observed between the age-at-onset of RLS symptoms and baseline IRLS total score (correlation r = -0.06), and between dose administered at Week 12 last observation carried forward (LOCF) and age-at-onset (r = -0.04). The age-at-onset by treatment interaction was non-significant (P = 0.952 for the IRLS and P = 0.716 for the CGI-I scale), indicating there was no significant relationship between age-at-onset and the magnitude of ropinirole treatment effect. Conclusions: These data suggest that ropinirole provides effective relief of symptoms, regardless of age at RLS symptom onset.",
keywords = "Dopamine agonist, Early-onset RLS, Late-onset RLS, Restless legs syndrome, RLS, RLS onset age, Ropinirole",
author = "Richard Allen and Ritchie, {Sally Y.}",
year = "2008",
month = "12",
doi = "10.1016/j.sleep.2007.08.017",
language = "English (US)",
volume = "9",
pages = "899--902",
journal = "Sleep Medicine",
issn = "1389-9457",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset

AU - Allen, Richard

AU - Ritchie, Sally Y.

PY - 2008/12

Y1 - 2008/12

N2 - Objective: To determine whether clinical response to the dopamine agonist, ropinirole, in the treatment of primary restless legs syndrome (RLS), depends upon the age-at-onset of RLS symptoms. Methods: Pooled data from four 12-week, randomized, double-blind, placebo-controlled studies of ropinirole in patients with moderate-to-severe primary RLS were analyzed post hoc. The relationship between age-at-onset and response to treatment, based on change from the baseline International Restless Legs Syndrome Study Group (IRLSSG) rating scale (the International Restless Legs Scale [IRLS]) total score and the proportion of responders (rated 'much'/'very much' improved) on the Clinical Global Impression-Improvement (CGI-I) scale, was explored. Results: The range of age-at-onset of RLS symptoms was 2-75 years. No relationship was observed between the age-at-onset of RLS symptoms and baseline IRLS total score (correlation r = -0.06), and between dose administered at Week 12 last observation carried forward (LOCF) and age-at-onset (r = -0.04). The age-at-onset by treatment interaction was non-significant (P = 0.952 for the IRLS and P = 0.716 for the CGI-I scale), indicating there was no significant relationship between age-at-onset and the magnitude of ropinirole treatment effect. Conclusions: These data suggest that ropinirole provides effective relief of symptoms, regardless of age at RLS symptom onset.

AB - Objective: To determine whether clinical response to the dopamine agonist, ropinirole, in the treatment of primary restless legs syndrome (RLS), depends upon the age-at-onset of RLS symptoms. Methods: Pooled data from four 12-week, randomized, double-blind, placebo-controlled studies of ropinirole in patients with moderate-to-severe primary RLS were analyzed post hoc. The relationship between age-at-onset and response to treatment, based on change from the baseline International Restless Legs Syndrome Study Group (IRLSSG) rating scale (the International Restless Legs Scale [IRLS]) total score and the proportion of responders (rated 'much'/'very much' improved) on the Clinical Global Impression-Improvement (CGI-I) scale, was explored. Results: The range of age-at-onset of RLS symptoms was 2-75 years. No relationship was observed between the age-at-onset of RLS symptoms and baseline IRLS total score (correlation r = -0.06), and between dose administered at Week 12 last observation carried forward (LOCF) and age-at-onset (r = -0.04). The age-at-onset by treatment interaction was non-significant (P = 0.952 for the IRLS and P = 0.716 for the CGI-I scale), indicating there was no significant relationship between age-at-onset and the magnitude of ropinirole treatment effect. Conclusions: These data suggest that ropinirole provides effective relief of symptoms, regardless of age at RLS symptom onset.

KW - Dopamine agonist

KW - Early-onset RLS

KW - Late-onset RLS

KW - Restless legs syndrome

KW - RLS

KW - RLS onset age

KW - Ropinirole

UR - http://www.scopus.com/inward/record.url?scp=55649109481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649109481&partnerID=8YFLogxK

U2 - 10.1016/j.sleep.2007.08.017

DO - 10.1016/j.sleep.2007.08.017

M3 - Article

C2 - 18024167

AN - SCOPUS:55649109481

VL - 9

SP - 899

EP - 902

JO - Sleep Medicine

JF - Sleep Medicine

SN - 1389-9457

IS - 8

ER -